Roche Diagnostics (Roche; Basel, Switzerland), a biotech company focused on research-based healthcare, has formed an alliance with med fusion LLC (Lewisville, Texas, USA), an integrated laboratory and clinical trials service organization, designating the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.
Established in 2002, Roche's MCOE program allows noncompeting regional laboratories across the United States to collaborate and capitalize on molecular testing instruments in order to advance test methodologies and technology.
As a nationally recognized Roche MCOE, med fusion's molecular diagnostics laboratory will offer healthcare professionals and patients some of the latest and most advanced molecular technologies, including Roche's cobas 4800 BRAF V600 Mutation Test, a companion diagnostic that identifies patients who are eligible for treatment with the ZELBORAF (vemurafenib) drug for inoperable or metastatic melanoma, a deadly form of skin cancer.
"Roche is very pleased to welcome med fusion into the Molecular Center of Excellence alliance," said Whitney Green, senior vice president, molecular diagnostics, Roche Diagnostics Corporation. "We value their expertise and look forward to working together in implementing molecular technologies in the advancement of personalized medicine.
"med fusion is one of 35 labs in the United States and 3 in Texas that have received this accolade. According to Dr. Thomas Lohmann, chief medical officer, med fusion, the partnership with Roche will help the company provide healthcare professionals and patients with improved diagnostic services."This relationship with Roche will help keep med fusion on the leading edge of technology and help ensure that we are supporting physicians and patients with the most advanced molecular technologies," added Dr. Lohmann.Roche is an industry leader in pharmaceuticals and diagnostics, providing a broad range of products and services for the early detection, prevention, diagnosis, and treatment of diseases.
